Sign in

Predictive Oncology Inc. (POAI) Q2 2025 Earnings Summary

Executive Summary

  • Q2 2025 revenue was $2,682, down 96.0% YoY and 97.6% QoQ as sales of tumor-specific 3D models and 3D kits declined; loss from continuing operations narrowed to approximately $2.0M with EPS (continuing) at $(0.22) vs $(0.53) in Q2 2024 .
  • Liquidity tightened with cash at $0.51M and stockholders’ deficit at $(1.65)M at quarter-end; management secured a $10M standby equity purchase agreement (SEPA) with Yorkville for flexible funding .
  • Commercial focus shifts to ChemoFx: U.S. expansion and a de novo European launch are anticipated in Q4 2025; management frames this as a 2026+ revenue catalyst .
  • No Q2 2025 earnings call transcript or Street consensus was available; comparisons to estimates are not applicable (S&P Global consensus unavailable) .

What Went Well and What Went Wrong

What Went Well

  • Secured flexible capital via a $10M SEPA with Yorkville to advance initiatives; CEO: the agreement is “an efficient and flexible source of capital” and the company is “grateful to the Yorkville team for their support” .
  • Pipeline/technology progress: two proprietary 3D liver toxicity organoid models for Labcorp (human and rat), enhancing preclinical evaluation capabilities .
  • Drug repurposing traction: initial screening identified Afuresertib (breast), Alisertib (colon), and Entinosta (colon) as candidates for further exploration; effort now expanding to additional abandoned drugs .

What Went Wrong

  • Revenue deteriorated materially to $2,682 due to decreased sales of tumor-specific 3D models and 3D kits; gross profit turned negative (loss) .
  • Cash balance fell to $506,078 and stockholders’ deficit widened to $(1,653,400), underscoring near-term financing risk despite the SEPA backstop .
  • Operating expenses rose sequentially (Sales & Marketing up as digital marketing resumed), keeping operating loss elevated despite cost actions earlier in the year .

Financial Results

Quarterly summary

MetricQ4 2024Q1 2025Q2 2025
Revenue ($)$611,585*$110,310 $2,682
Gross Profit ($)$320,959*$65,192 $(15,539)
Gross Margin (%)52.5% (320,959/611,585)*59.1% (65,192/110,310) −579.4% (−15,539/2,682)
Total Operating Expenses ($)$2,735,233*$2,352,239 $2,644,329
EBIT / Operating (Loss) ($)$(2,123,648)*$(2,287,047) $(2,659,868)
Net (Loss) ($)$(2,169,594)*$(2,442,873) $(2,070,462)
Diluted EPS – Continuing Ops ($)N/A$(0.32) $(0.22)
Cash and Equivalents ($)$734,673 $3,087,588 $506,078
*Values retrieved from S&P Global.

Q2 2025 vs prior periods

MetricQ2 2024Q1 2025Q2 2025YoY ChangeQoQ Change
Revenue ($)$67,255 $110,310 $2,682 −96.0% −97.6%
EPS – Continuing ($)$(0.53) $(0.32) $(0.22) +$0.31 (less negative) +$0.10 (less negative)
Operating (Loss) ($)N/A$(2,287,047) $(2,659,868) N/A+$372,821 (worse)

Estimates vs Actuals (S&P Global)

MetricQ2 2025 ConsensusQ2 2025 Actual
Revenue ($)N/A (no estimate)$2,682
EPS – Primary ($)N/A (no estimate)$(0.22) (continuing)
S&P Global consensus was unavailable for Q2 2025; therefore, beat/miss analysis vs Street is not applicable.

KPIs and cash flow

KPIQ4 2024Q1 2025Q2 2025
Cash & Equivalents ($)$734,673 $3,087,588 $506,078
Stockholders’ Equity (Deficit) ($)$(202,610) $(145,796) $(1,653,400)
Net cash used in operating activities – Continuing Ops ($)N/A$(985,840) (Q1) $(4,280,632) (H1)

Segment context (latest disclosed)

SegmentFY 2024 Revenue ($)Comment
Eagan$1,539,005 STREAMWAY systems drove mix in 2024 .
Pittsburgh$84,812 Lower 3D model revenue vs 2023 .
No Q2 2025 segment breakout was provided; management cited decreased sales of tumor-specific 3D models and 3D kits as the primary driver of revenue decline .

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
ChemoFx launch timing (EU)2025“Planned European launch” (Q1 update) “Anticipated in Q4 2025” Timing specified (narrowed to Q4)
ChemoFx U.S. expansion2025Expanded availability planned Aggressive expansion underway; channels/end‑users discussions Execution progressing
Financial metrics (revenue, margins, OpEx, tax)2025None disclosedNone disclosedMaintained (no quantitative guidance)

Earnings Call Themes & Trends

No Q2 2025 earnings call transcript was found in our document set; themes are drawn from the Q2 press release and contemporaneous company communications.

TopicPrevious Mentions (Q4 2024)Previous Mentions (Q1 2025)Current Period (Q2 2025)Trend
AI/technology initiativesEntered biomarker discovery; Tecan collaboration highlighted .Repurposing registry; three candidates identified; Tecan study presented at SLAS .Expanded repurposing screen; liver toxicity organoids for Labcorp .Broadening use cases and partnerships.
ChemoFxPlanned EU launch and U.S. expansion .Planned EU launch; expanded U.S. availability .EU de novo launch and U.S. expansion anticipated Q4 2025 .Commercialization nearing execution.
Partnerships/BDStrategic alternatives/merger context (Renovaro) .Focus sharpened post-Skyline sale; BD highlighted .Every Cure collaboration announced Sept 4 (post-quarter) .External validation building.
Liquidity/capitalCash down; deficit emerged .Cash boosted by asset sale/financing .Cash tight; $10M SEPA for flexibility .Funding optionality added, cash remains constrained.
Cost structureCost savings initiatives in 2024 .Lower G&A and S&M vs prior year .Mixed: G&A up modestly; S&M up on digital marketing .Selective reinvestment as go‑to‑market approaches.

Management Commentary

  • “We… took meaningful steps toward strengthening our financial position while also creating a foundation from which to generate meaningful revenues in 2026 and beyond.” – Raymond Vennare, CEO .
  • “The share purchase agreement… with Yorkville Advisors represents an efficient and flexible source of capital that we can utilize to advance these initiatives.” – CEO .
  • On ChemoFx: “By testing multiple chemotherapies on a patients’ cancer cells before treatment selection, ChemoFx helps determine which chemotherapies are more likely to be effective… enabling better and faster treatment decisions” .
  • On Labcorp collaboration: the 3D liver toxicity organoids “enable the prediction of in vivo drug clearance, drug transport and hepatotoxicity” – Dr. Arlette Uihlein, SVP .

Q&A Highlights

  • The company did not host a Q2 2025 earnings call transcript in our source set; no Q&A to report (management commentary drawn from press releases/shareholder letter) .

Estimates Context

  • S&P Global consensus estimates for Q2 2025 EPS and revenue were not available; thus, no beat/miss determination vs Street can be made for the quarter. Actuals: revenue $2,682; EPS (continuing) $(0.22) .
  • Implication: estimate models, where they exist, likely need to reflect materially lower near‑term services revenue and a heavier reliance on 2H 2025 commercialization milestones (ChemoFx) and partnerships rather than near-term product sales .

Key Takeaways for Investors

  • Liquidity is the primary near-term focus: quarter-end cash of ~$0.5M is thin, but a $10M SEPA provides an at-the-market funding option; monitor utilization pace and potential dilution vs runway extension .
  • Commercial catalyst path: ChemoFx U.S. expansion and EU de novo launch anticipated in Q4 2025; tangible execution there is the most visible route to revenue inflection into 2026 .
  • Revenue base is currently minimal and volatile as the company pivots; without Street coverage, near-term prints may be noisy—position sizing should reflect binary commercialization and BD outcomes .
  • Partnership validation is accruing (Labcorp organoids; Every Cure repurposing collaboration); additional data readouts or agreements would support the strategic pivot and could drive sentiment .
  • Operating discipline remains important: despite YoY improvement in EPS, OpEx ticked up sequentially; watch spending as commercialization ramps .
  • Legacy segments: historic mix skewed to Eagan in 2024; current strategy prioritizes AI/biobank/assay-led offerings, implying different revenue drivers ahead .

Notes:

  • Where values are marked with an asterisk (*), they are Values retrieved from S&P Global.
  • No S&P Global consensus estimates were available for Q2 2025; all estimate-related rows reflect unavailability.

Best AI for Equity Research

Performance on expert-authored financial analysis tasks

Fintool-v490%
Claude Sonnet 4.555.3%
o348.3%
GPT 546.9%
Grok 440.3%
Qwen 3 Max32.7%